More stunning information is being uncovered of both government and vaccine maker documents.  It appears the vaccine is more than one of several possible treatments all in one injection.  “We are told the mRNA produces just a small sequence of the spike protein.  Through my research, I found separate patents for the spike protein.  There are seven different spike proteins in the actual patents.  This should all be part of the SARS COV II patent.  It should not have a separate patent. . . .They all do different things per the patent and per the research.”

So, instead of getting one experimental mRNA injection, could people be injected with a cocktail of separate and different spike proteins?  Karen Kinston says, “I am hypothesizing based on the spike proteins having separate patents and separate licensing deals.  The scientists say they jimmied the spike protein independent of the mRNA viral sequence.   What I am saying, in some of what they are calling vaccines, yes, people are being injected with mRNA producing spike proteins.  They can also be injected directly with spike proteins . . . made separately and frozen separately.  These spike proteins do have their own patents, they do have their own separate licensing agreements. . . . So, the spike proteins could be made separately and frozen separately, these poisons, and then encapsulated and stuck in the formulation.  That is what I am saying. . . . Keep in mind, in the world patent . . . it says in some embodiments can include a delivery device, and that can deliver an agent or a toxin over a period of hours, days, weeks, months or years. . . . This is important for a legal reason because every lawsuit says people were injected with mRNA, which produces a toxin, which is a spike protein.  But it turns out, the toxin was in there independent of the mRNA. . . . It’s not a vax.  It’s just a direct bioweapon.”


Use the toolbar at top to open the document.


Who's making this mess?

[US Patent & Trademark Office, Patent Full Text and Image Database]

( 1 of 1 )

United States Patent 9,539,210
von Andrian ,   et al. January 10, 2017

Vaccine nanotechnology

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

Inventors: von Andrian; Ulrich H. (Chestnut Hill, MA), Farokhzad; Omid C. (Waban, MA), Langer; Robert S. (Newton, MA), Junt; Tobias (Schorndorf, DE), Moseman; Elliott Ashley (Jamaica Plain, MA), Zhang; Liangfang(San Diego, CA), Basto; Pamela (Cambridge, MA), Iannacone; Matteo (Milan, IT), Alexis; Frank (Greenville, SC)
Name City State Country Type

Massachusetts Institute of Technology
The Brigham and Women's Hospital, Inc.
President and Fellows of Harvard College
The Children's Medical Center Corporation
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
The Brigham and Women's Hospital, Inc. (Boston, MA)
President and Fellows of Harvard College (Cambridge, MA)
The Children's Medical Center Corporation (Boston, MA)
Family ID: 40403998
Appl. No.: 13/844,382
Filed: March 15, 2013

Prior Publication Data

Document Identifier Publication Date
US 20140314865 A1 Oct 23, 2014

Related U.S. Patent Documents


Application Number Filing Date Patent Number Issue Date
PCT/US2008/011932 Oct 12, 2008
60979596 Oct 12, 2007


Karen Kingston is a business analyst and strategic marketer in the biotech industry. She has over 25 years of experience in marketing, business development, sales, public speaking, and strategic consulting.